Breadcrumb

[A13-25] Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil - Benefit assessment according to § 35a Social Code Book V (dossier assessment)

Overview

Overview

Commission: Commission awarded on 2013-06-14 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Dossier assessment  [PDF, 759 kB]Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [A17-59] Elvitegravir/cobicistat/emtricitabine/ tenofovir disoproxil (HIV-1 in adolescents) – Benefit assessment according to §35a Social Code Book (SGB) V
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2013-09-16 Extract of dossier assessment 347 kBPDFdownload file
2013-09-16 Dossier assessment 759 kBPDFdownload file


At a glance


Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close